Your body does produce DMT, but the amounts detected in the brain are so small that they fall far short of what would be needed to produce a psychoactive trip. The idea that meditation, breathwork, or near-death states trigger a flood of endogenous DMT large enough to cause hallucinations is, as of now, unsupported by direct measurement. That does not mean the question is uninteresting. Researchers have confirmed that mammalian brains synthesize DMT through a known enzymatic pathway, and there are credible hypotheses about what it might be doing at those tiny concentrations, just not what the popular narrative suggests.
Your Brain Does Produce DMT
The claim that the human body makes its own DMT is not fringe speculation. It is established biochemistry. DMT is synthesized from tryptophan, an amino acid you get from food, through a series of enzymatic steps. First, tryptophan is converted to tryptamine. Then an enzyme called indolethylamine-N-methyltransferase (INMT) adds two methyl groups to tryptamine, producing DMT.1PubMed Central. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain INMT is found in multiple tissues throughout the body, and dysregulation of its activity has been linked to various conditions including neuropsychiatric disorders and neurodegeneration.2PubMed Central. Implications of Indolethylamine N-Methyltransferase (INMT) in Health and Disease: Biological Functions, Disease Associations, Inhibitors, and Analytical Approaches
In 2019, researchers directly measured DMT in the brains of living rats using microdialysis probes and found baseline concentrations averaging about 0.56 nM, with a range of roughly 0.05 to 1.8 nM.1PubMed Central. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain That was a significant finding because it confirmed DMT is not just present in trace amounts in blood or urine (which had been known for decades) but is actively produced and released in the brain’s extracellular space. The question is what those concentrations mean functionally.
Why the Pineal Gland Story Does Not Hold Up
The most popular version of the “natural DMT release” idea comes from a hypothesis, widely attributed to Rick Strassman’s 2001 book, that the pineal gland floods the brain with DMT during birth, death, and dreaming. It is a compelling narrative, but the evidence runs against it. The adult pineal gland weighs less than 0.2 grams. Its primary job is producing roughly 30 micrograms per day of melatonin, a hormone involved in sleep-wake cycles. The concentrations of DMT detected in the brain are far too low to produce psychoactive effects.3PubMed. N,N-dimethyltryptamine and the pineal gland: Separating fact from myth
More directly, the 2019 rat study tested this by comparing normal rats to rats that had their pineal glands surgically removed. DMT was still detectable in the brains of pinealectomized animals, with cortical levels showing no significant difference between the two groups.1PubMed Central. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain The cortex itself appears capable of making DMT independently. A more recent study went further, testing whether endogenous DMT accumulates in rat brain tissue when the enzyme that normally breaks it down is blocked. Even with that enzyme inhibited, endogenous DMT levels remained below the study’s detection limit, and there was little evidence that DMT is stored or retained in serotonin-releasing neurons the way neurotransmitters typically are.4Neuropharmacology. N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain
None of this means the pineal gland produces zero DMT. It may contribute some. But the idea that it serves as a reservoir capable of releasing a psychedelic dose under the right conditions is not supported by what has actually been measured. The cortex seems to be at least as important a source, and neither region produces anywhere near enough to alter consciousness.
The Concentration Gap
This is the central problem with every “natural DMT release” claim. Pharmacokinetic modeling in humans has estimated that the plasma concentration of DMT needed to produce half the maximum psychedelic effect is about 95 nM.5PubMed Central. Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine – Implications for dose considerations Compare that to the baseline brain concentrations in rats, which averaged around 0.56 nM. That is roughly 170 times lower than what is needed to produce even a mild psychedelic effect at the receptor site. And DMT is cleared from the body extremely fast. In the first pharmacokinetic study to track DMT levels in humans after a slow intravenous infusion, researchers confirmed that DMT is rapidly eliminated by the enzyme MAO-A.6PubMed Central. Pharmacokinetics of N,N-dimethyltryptamine in Humans
So for any natural process to produce a genuine DMT trip, the brain would need to suddenly generate at least a hundred times more DMT than it normally contains, and somehow prevent MAO-A from immediately breaking it down. No measurement has ever captured anything close to that scenario in a living brain. The 2019 rat study did observe increases in cortical DMT levels during cardiac arrest, which is intriguing, but even those elevated levels were not confirmed to reach psychoactive thresholds.
What About Breathwork?
Holotropic breathwork, circular breathwork, and similar hyperventilation-based practices are frequently described online as methods to “release endogenous DMT.” The subjective experiences can indeed be powerful: people report visual phenomena, ego dissolution, emotional catharsis, and altered senses of time. But the mechanism appears to have nothing to do with DMT production.
A 2025 study measuring physiological and experiential effects of circular breathwork found that the altered states arose from a straightforward cause: deliberate hyperventilation lowered carbon dioxide levels in the blood, and that drop in CO2 was significantly correlated with the onset of altered states of consciousness. Using standard questionnaires, the researchers found that the breathwork-induced experiences resembled psychedelic states across several experiential domains, including ego dissolution, and that deeper altered states predicted improved well-being and reduced depressive symptoms afterward.7PubMed Central. Decreased CO2 saturation during circular breathwork supports emergence of altered states of consciousness
The resemblance to psychedelic experiences is real, but resemblance is not mechanism. Lowered CO2 changes blood pH, alters cerebral blood flow, and can produce tingling, visual disturbances, and shifts in consciousness through well-understood physiological pathways. None of the breathwork research has measured a spike in endogenous DMT. The subjective similarity to a DMT experience does not require DMT to be the explanation, and so far nobody has tested that claim directly in humans.
Meditation and DMT
Long-term meditators sometimes report experiences that overlap with psychedelic phenomenology: feelings of unity, visual phenomena, and dissolution of the sense of self. This has led to speculation that deep meditation might elevate endogenous DMT. One study placed experienced meditators in a retreat setting and compared a group given DMT plus harmine (an MAO inhibitor that slows DMT breakdown) with a placebo group. The meditators on placebo showed increased segregation between brain networks on resting-state imaging, while the DMT-harmine group showed increased connectivity within the visual network and between visual and attention networks.8PubMed Central. Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat
The interesting finding is that meditation and exogenous DMT produced different patterns of brain connectivity, not the same one. That does not rule out some overlap at the experiential level, but it works against the idea that meditation is simply triggering DMT release. The brain changes induced by meditation appear to be their own phenomenon rather than a pharmacological mimic of a DMT trip.
Near-Death Experiences and the DMT Connection
Near-death experiences (NDEs) are perhaps the most emotionally compelling context for the endogenous DMT hypothesis. People who survive cardiac arrest or other life-threatening events sometimes report tunnels of light, encounters with entities, life reviews, feelings of profound peace, and a sense of crossing a threshold. The idea that a surge of DMT causes these experiences gained traction because DMT, when given to healthy volunteers, can produce strikingly similar phenomenology.
In a controlled study, 13 volunteers received DMT intravenously. All of them scored above the standard cutoff on a near-death experience questionnaire, and their total NDE scores were statistically comparable to those given by people who had reported actual near-death experiences. Fifteen of the 16 items on the NDE scale were scored higher under DMT than placebo. The one area where actual NDE survivors scored higher was the item about coming to a “border or point of no return,” though that difference did not survive statistical correction.9PubMed Central. DMT Models the Near-Death Experience
A within-subject comparison study found significant overlap between near-death and psychedelic experiences in terms of mystical-type effects, including spiritual experience, feelings of unity, insightfulness, and blissful states. Low-level sensory effects, however, diverged between the two types of experience.10Neuroscience of Consciousness. Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects A separate case study comparing one individual’s NDE with a later 5-MeO-DMT experience found strong overlap in ego dissolution and transcendence of time and space, but certain NDE-specific themes like life review and encounters with deceased relatives did not appear in the psychedelic session.11PubMed Central. This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience
The phenomenological overlap is genuinely striking. But similarity in experience does not prove a shared chemical cause. EEG research on DMT has shown that the compound produces a characteristic collapse of alpha and beta brain rhythms alongside an emergence of theta and delta rhythms, a pattern the researchers compared to the brain’s switch from processing external information to internally-driven processing, as occurs in REM sleep dreaming.12PubMed Central. Neural correlates of the DMT experience assessed with multivariate EEG It is possible that NDEs, DMT experiences, and vivid dreams all involve the brain shifting into a similar internally-generated processing mode, but that the trigger for each is different. An oxygen-starved brain, an exogenous psychedelic, and the normal sleep cycle could all push the brain toward the same kind of state without any of them requiring endogenous DMT to do so.
What Endogenous DMT Might Actually Be Doing
If the tiny amounts of DMT in the brain are not enough to cause hallucinations, why does the brain bother making it? Researchers have found evidence pointing toward a protective role rather than a perceptual one. In cell culture experiments using human brain cells, DMT significantly increased the survival of cortical neurons and immune-like microglia cells under conditions of severe oxygen deprivation. This protective effect worked through the sigma-1 receptor and was associated with decreased activity of a key oxygen-sensing pathway, suggesting that DMT may help brain cells endure low-oxygen conditions through a mechanism that does not depend on the usual hypoxia response.13PubMed Central. The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells The researchers speculated that DMT may be produced endogenously in situations of stress to help protect the brain from damage caused by oxygen deprivation.
DMT also appears to have immunomodulatory effects outside the brain. In experiments on human immune cells derived from blood monocytes, both DMT and the related compound 5-MeO-DMT reduced the production of several inflammatory signaling molecules while increasing the production of an anti-inflammatory one, all through the sigma-1 receptor. The researchers described this as the first demonstration of DMT’s immunomodulatory potential on human immune cells and suggested that endogenous dimethyltryptamines may function as natural regulators of inflammation and immune balance.14PubMed Central. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells
There is also the neuroplasticity angle. Psychedelics as a class, including DMT, have been shown to promote structural and functional changes in neurons, increasing the complexity of dendritic branching and the number of synaptic connections. These structural changes appear to involve stimulation of the TrkB, mTOR, and serotonin 2A receptor signaling pathways.15PubMed Central. Psychedelics Promote Structural and Functional Neural Plasticity One leading model suggests that serotonin 2A receptor activation triggers a positive feedback loop involving BDNF (a growth factor for neurons) and sustained stimulation of AMPA receptors, which together drive lasting structural changes.16Neuropsychopharmacology. Towards an understanding of psychedelic-induced neuroplasticity Whether the very low endogenous concentrations of DMT contribute to baseline neuroplasticity is unknown, but the enzymatic machinery to produce it is present in many brain regions, which at least leaves the door open.
DMT Across the Animal Kingdom
One of the more thought-provoking aspects of endogenous DMT is how widespread it appears to be. The biosynthetic pathways for DMT have been found across a range of species, not just mammals. A 2025 review noted that this widespread evolutionary conservation suggests DMT may play roles in development and in helping cells adapt to environmental challenges.17PubMed. Exploring DMT: Endogenous role and therapeutic potential If DMT were merely a metabolic accident or a trivial byproduct, you would not expect the enzymes that produce it to be preserved so consistently across evolutionary time. The conservation of INMT in diverse species points toward some functional significance, even if that function turns out to be mundane: cellular stress response, immune modulation, or a housekeeping role in tryptophan metabolism rather than anything related to consciousness.
Why “Natural DMT Release” Guides Are Misleading
Search results for this topic are saturated with listicles promising techniques to boost your body’s DMT production: specific breathing patterns, hours-long meditation sits, sleep deprivation, fasting, darkness retreats. The problem is not that these practices are dangerous (most are not, though extended hyperventilation carries its own risks). The problem is that none of them have been shown to meaningfully increase DMT concentrations in the human brain, and even if they did, the gap between endogenous levels and psychoactive levels is enormous.
The experiences people have during breathwork, meditation, sensory deprivation, or fasting can be genuinely profound. They can involve visual phenomena, emotional breakthroughs, feelings of interconnectedness, and altered body perception. But attributing these to DMT release conflates the subjective quality of an experience with a specific neurochemical mechanism. Your brain has many ways to generate altered states, including changes in blood gases, shifts in network connectivity, modulation of default mode network activity, and altered thalamic gating of sensory input. DMT is one compound among many that can produce certain experiential features, and the fact that an experience feels similar to what DMT users describe does not mean DMT caused it.
The honest state of the science is this: your body makes DMT, but in quantities that appear designed for cellular signaling and stress protection rather than for producing visions. The practices marketed as DMT-release techniques may produce altered states through their own legitimate mechanisms, and those mechanisms are interesting in their own right. Framing them as DMT hacks undersells the real neuroscience of what is happening and oversells a hypothesis that has not survived contact with measurement.
What Clinical DMT Research Is Actually Finding
While the “natural release” narrative occupies the popular conversation, the more substantive scientific story involves clinical trials using DMT administered at known doses under controlled conditions. This research is producing findings that matter regardless of whether endogenous DMT turns out to be pharmacologically relevant.
The rapid clearance of DMT, confirmed in pharmacokinetic studies showing a clearance rate of about 26 liters per minute (an extremely high value indicating the body eliminates DMT almost independently of blood flow), makes it an appealing candidate for controlled therapeutic use because the effects are short-lived compared to other psychedelics.5PubMed Central. Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine – Implications for dose considerations A session with intravenous DMT can be completed in under an hour, versus six or more hours for psilocybin, which has practical advantages for clinical settings. Trials investigating DMT for depression, anxiety, and substance use disorders are underway, and the neuroplasticity findings from cell culture and animal studies provide a plausible biological rationale for why a single session might produce lasting changes in mood and cognition.
The sigma-1 receptor pathway through which DMT protects cells against oxygen deprivation is also drawing interest for stroke and cardiac arrest research. If a compound that the brain already makes can reduce cell death during oxygen deprivation, there may be a way to harness that pharmacologically, using exogenous DMT delivered at controlled therapeutic doses rather than relying on the body to produce quantities it has never been shown to produce on its own. The irony is that the most promising medical applications of DMT have nothing to do with trying to coax more of it out of your pineal gland and everything to do with understanding its receptor pharmacology well enough to use it as a drug.